Biomed Industries, Inc. Press Releases

• Published on June 11, 2024 - 12:00 GMT

  

  Biomed Industries, Inc. to Present a New Quadruple Agonist for Weight Loss at ADA Congress and Euro Obesity Conference

  Biomed Industries, Inc. to Present a New Quadruple Receptor Agonist for Treatment of Obesity at ADA’s 84th Scientific Sessions and Euro Obesity Conference-2024 SAN JOSE, CA, USA, June 11, 2024 /⁨EINPresswire.com⁩/ -- Biomed Industries, Inc. (Biomed), a …

  Distribution channels: Chemical Industry, Companies ...
• Published on May 6, 2024 - 10:00 GMT

  

  Biomed Industries, Inc. Announces Breakthrough Drug for the Treatment and Prevention of Stroke

  Biomed's NA-911 represents a breakthrough in stroke treatment, focusing on neurogenesis showing potential in the treatment of stroke and facilitating recovery. SAN JOSE, CALIFORNIA, UNITED STATES, May 6, 2024 /⁨EINPresswire.com⁩/ -- Biomed Industries, …

  Distribution channels: Chemical Industry, Companies ...
• Published on March 12, 2024 - 12:49 GMT

  

  Biomed Industries, Inc. announces the first Triple IGF-1/GLP-1/GIP receptor agonist NA-931 for the treatment of obesity

  NA-931, an oral drug and the triple receptor agonist, reduces body weight up to 26% without muscle loss and less adverse events than existing treatments. SAN JOSE, CALIFORNIA, UNITED STATES, March 12, 2024 /⁨EINPresswire.com⁩/ -- Biomed Industries, Inc. …

  Distribution channels: Business & Economy, Chemical Industry ...
• Published on October 4, 2023 - 12:00 GMT

  

  Biomed Industries, Inc. to showcase its research at Clinical Trials on Alzheimer’s Disease Conference 2023 in Boston

  Biomed highlights failure of anti-amyloid drugs, presenting new neurogenesis hypothesis and clinical results of NA-831 for treatment of Alzheimer's disease SAN JOSE, CA, USA, October 4, 2023 /⁨EINPresswire.com⁩/ -- Biomed Industries,™ Inc. Showcases …

  Distribution channels: Chemical Industry, Healthcare & Pharmaceuticals Industry ...